nach oben

Forensic Toxicology

Erschienen in:

30.12.2022 | Short Communication

Δ⁹-Tetrahydrocannabinol stimulation of estrogen receptor-positive MCF-7 breast cancer cell migration: Interfering interaction with the estrogenic milieu

verfasst von: Shuso Takeda, Masayo Hirao-Suzuki, Hironori Aramaki, Kazuhito Watanabe

Erschienen in: Forensic Toxicology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The effects of extended Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exposure on estrogen receptor-positive human breast cancer MCF-7 cells have been investigated; however, the effects of Δ⁹-THC exposure for a shorter duration remain unclear. In this study, we sought to study whether Δ⁹-THC stimulates the migration of MCF-7 cells under both estrogenic and estrogen-deprived conditions over a short period (approximately 6 h).

Methods

MCF-7 cells were treated with Δ⁹-THC under estrogenic or estrogen-deprived conditions, and cell migration was subsequently analyzed.

Results

Δ⁹-THC-stimulated migration of MCF-7 cells 6 h after exposure was only observed in the estrogen-deprived condition. However, Δ⁹-THC-mediated migration was counteracted under estrogenic conditions without affecting cell proliferation and estrogen receptor expression during this period.

Conclusions

Δ⁹-THC can stimulate MCF-7 cell migration under estrogen-deprived conditions; however, there is an interfering interaction between Δ⁹-THC and the estrogenic milieu that influences the migration of MCF-7 cells.

Gertsch J, Pertwee RG, Di Marzo V (2010) Phytocannabinoids beyond the Cannabis plant—do they exist? Br J Pharmacol 160:523–529. https://doi.org/10.1111/j.1476-5381.2010.00745.x CrossRefPubMedPubMedCentral

Watanabe K, Motoya E, Matsuzawa N, Funahashi T, Kimura T, Matsunaga T, Arizono K, Yamamoto I (2005) Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206:471–478. https://doi.org/10.1016/j.tox.2004.08.005 CrossRefPubMed

Takeda S, Yoshida K, Nishimura H, Harada M, Okajima S, Miyoshi H, Okamoto Y, Amamoto T, Watanabe K, Omiecinski CJ, Aramaki H (2013) Δ ⁹-Tetrahydrocannabinol disrupts estrogen-signaling through up-regulation of estrogen receptor β (ERβ). Chem Res Toxicol 26:1073–1079. https://doi.org/10.1021/tx4000446 CrossRefPubMedPubMedCentral

Takeda S (2014) Δ ⁹-Tetrahydrocannabinol targeting estrogen receptor signaling: The possible mechanism of action coupled with endocrine disruption. Biol Pharm Bull 37:1435–1438. https://doi.org/10.1248/bpb.b14-00226 CrossRefPubMed

Takeda S, Ikeda E, Okazaki H, Watanabe K, Aramaki H (2017) Δ ⁹-tetrahydrocannabinol effects in human breast cancer. In: Preedy VR (ed) Handbook of Cannabis and related pathologies biology pharmacology diagnosis and treatment. Elsevier Inc, New York, pp 722–728. https://doi.org/10.1016/B978-0-12-800756-3.00085-5 CrossRef

Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A (2016) Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. J Nat Prod 79:324–331. https://doi.org/10.1021/acs.jnatprod.5b00949 CrossRefPubMed

Badowski ME, Yanful PK (2018) Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag 14:643–651. https://doi.org/10.2147/TCRM.S126849 CrossRefPubMedPubMedCentral

Solomon J, Cocchia MA, Gray R, Shattuck D, Vossmer A (1976) Uterotrophic effect of delta-9-tetrahydrocannabinol in ovariectomized rats. Science 192:559–561. https://doi.org/10.1126/science.1257790 CrossRefPubMed

Virgo BB (1980) The uterotrophic effect of delta-9-tetrahydrocannabinol in ovariectomized rats and mice. Res Commun Chem Pathol Pharmacol 29:613–616 PubMed

10.

von Bueren AO, Schlumpf M, Lichtensteiger W (2008) Delta(9)-tetrahydrocannabinol inhibits 17β-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. Anticancer Res 28:85–89

11.

Takeda S, Yamaori S, Motoya E, Matsunaga T, Kimura T, Yamamoto I, Watanabe K (2008) Δ ⁹-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology 245:141–146. https://doi.org/10.1016/j.tox.2007.12.019 CrossRefPubMed

12.

Takeda S, Yamamoto I, Watanabe K (2009) Modulation of Δ ⁹-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase. Toxicology 259:25–32. https://doi.org/10.1016/j.tox.2009.01.024 CrossRefPubMed

13.

Sauer MA, Rifka SM, Hawks RL, Cutler GBJ, Loriaux DL (1983) Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther 224:404–407 PubMed

14.

Ruh MF, Taylor JA, Howlett AC, Welshons WV (1997) Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol 53:35–41. https://doi.org/10.1016/s0006-2952(96)00659-4 CrossRefPubMed

15.

Pink JJ, Jordan VC (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321–2330 PubMed

16.

Lonard DM, Nawaz Z, Smith CL, O’Malley BW (2000) The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939–948. https://doi.org/10.1016/s1097-2765(00)80259-2 CrossRefPubMed

17.

Ahola TM, Manninen T, Alkio N, Ylikomi T (2002) G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 143:3376–3384. https://doi.org/10.1210/en.2001-211445 CrossRefPubMed

18.

Dong S, Terasaka S, Kiyama R (2011) Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells. Environ Pollut 159:212–218. https://doi.org/10.1016/j.envpol.2010.09.004 CrossRefPubMed

19.

Hirao-Suzuki M, Takeda S, Okuda K, Takiguchi M, Yoshihara S (2019) Repeated exposure to 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP), an active metabolite of bisphenol A, aggressively stimulates breast cancer cell growth in an estrogen receptor β (ERβ)-dependent manner. Mol Pharmacol 95:260–268. https://doi.org/10.1124/mol.118.114124 CrossRefPubMed

20.

Aramaki H, Tomiyasu N, Yoshimura H, Tsukamoto H (1968) Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gas chromatographies. Chem Pharm Bull 16:822–826. https://doi.org/10.1248/cpb.16.822 CrossRef

21.

Takeda S, Jiang R, Aramaki H, Imoto M, Toda A, Eyanagi R, Amamoto T, Yamamoto I, Watanabe K (2011) Δ ⁹-tetrahydrocannabinol and its major metabolite Δ ⁹-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors. J Pharm Sci 100:1206–1211. https://doi.org/10.1002/jps.22354 CrossRefPubMed

22.

Takeda S, Harada M, Su S, Okajima S, Miyoshi H, Yoshida K, Nishimura H, Okamoto Y, Amamoto T, Watanabe K, Omiecinski CJ, Aramaki H (2013) Induction of the fatty acid 2-hydroxylase ( FA2H) gene by Δ ⁹-tetrahydrocannabinol in human breast cancer cells. J Toxicol Sci 38:305–308. https://doi.org/10.2131/jts.38.305 CrossRefPubMedPubMedCentral

23.

Takeda S, Misawa K, Yamamoto I, Watanabe K (2008) Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab Dispos 36:1917–1921. https://doi.org/10.1124/dmd.108.020909 CrossRefPubMed

24.

Takeda S, Usami N, Yamamoto I, Watanabe K (2009) Cannabidiol-2′,6′-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor. Drug Metab Dispos 37:1733–1737. https://doi.org/10.1124/dmd.109.026930 CrossRefPubMed

25.

Hirao-Suzuki M, Koga T, Sakai G, Kobayashi T, Ishii Y, Miyazawa H, Takiguchi M, Sugihara N, Toda A, Ohara M, Takeda S (2020) Fatty acid 2-hydroxylase (FA2H) as a stimulatory molecule responsible for breast cancer cell migration. Biochem Biophys Res Commun 531:215–222. https://doi.org/10.1016/j.bbrc.2020.07.043 CrossRefPubMed

26.

Takeda S, Okajima S, Miyoshi H, Yoshida K, Okamoto Y, Okada T, Amamoto T, Watanabe K, Omiecinski CJ, Aramaki H (2012) Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicol Lett 214:314–319. https://doi.org/10.1016/j.toxlet.2012.08.029 CrossRefPubMedPubMedCentral

27.

Sakai G, Hirao-Suzuki M, Koga T, Kobayashi T, Kamishikiryo J, Tanaka M, Fujii K, Takiguchi M, Sugihara N, Toda A, Takeda S (2022) Perfluorooctanoic acid (PFOA) as a stimulator of estrogen receptor-negative breast cancer MDA-MB-231 cell aggressiveness: evidence for involvement of fatty acid 2-hydroxylase (FA2H) in the stimulated cell migration. J Toxicol Sci 47:159–168. https://doi.org/10.2131/jts.47.159 CrossRefPubMed

28.

Hirao-Suzuki M, Takeda S, Kodama Y, Takiguchi M, Toda A, Ohara M (2020) Metalloestrogenic effects of cadmium are absent in long-term estrogen-deprived MCF-7 cells: Evidence for the involvement of constitutively activated estrogen receptor α and very low expression of G protein-coupled estrogen receptor 1. Toxicol Lett 319:22–30. https://doi.org/10.1016/j.toxlet.2019.10.018 CrossRefPubMed

29.

Lu H-G, Zhan W, Yan L, Qin R-Y, Yan Y-P, Yang Z-J, Liu G-C, Li G-Q, Wang H-F, Li X-L, Li Z, Gao L, Chen G-Q (2014) TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion. Mol Med Rep 10:2595–2600. https://doi.org/10.3892/mmr.2014.2517 CrossRefPubMed

30.

Lillo MA, Nichols C, Seagroves TN, Miranda-Carboni GA, Krum SA (2017) Bisphenol A induces Sox2 in ER ⁺ breast cancer stem-like cells. Horm Cancer 8:90–99. https://doi.org/10.1007/s12672-017-0286-5 CrossRefPubMedPubMedCentral

31.

Bindal RD, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA (1988) Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol red. J Steroid Biochem 31:287–293. https://doi.org/10.1016/0022-4731(88)90352-4 CrossRefPubMed

32.

Mori K, Fujii R, Kida N, Takahashi H, Ohkubo S, Fujino M, Ohta M, Hayashi K (1990) Complete primary structure of the human estrogen-responsive gene (pS2) product. J Biochem 107:73–76. https://doi.org/10.1093/oxfordjournals.jbchem.a123014 CrossRefPubMed

33.

Friedl P, Alexander S (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147:992–1009. https://doi.org/10.1016/j.cell.2011.11.016 CrossRefPubMed

34.

Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174. https://doi.org/10.1038/nrc745 CrossRefPubMed

35.

Diamanti-Kandarakis E, Bourguignon J-P, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC (2009) Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev 30:293–342. https://doi.org/10.1210/er.2009-0002 CrossRefPubMedPubMedCentral

36.

Shanle EK, Xu W (2011) Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol 24:6–19. https://doi.org/10.1021/tx100231n CrossRefPubMed

37.

Wall ME, Perez-Reyes M (1981) The metabolism of Δ ⁹-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21:178S-189S. https://doi.org/10.1002/j.1552-4604.1981.tb02594.x CrossRefPubMed

38.

Heuberger JAAC, Guan Z, Oyetayo O-O, Klumpers L, Morrison PD, Beumer TL, van Gerven JMA, Cohen AF, Freijer J (2015) Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clin Pharmacokinet 54:209–219. https://doi.org/10.1007/s40262-014-0195-5 CrossRefPubMed

39.

Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM (1992) Marijuana smoking: effect of varying Δ ⁹-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 261:114–122 PubMed

40.

Gill EW, Jones G (1972) Brain levels of Δ1-tetrahydrocannabinol and its metabolites in mice–correlation with behaviour, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide. Biochem Pharmacol 21:2237–2248. https://doi.org/10.1016/0006-2952(72)90039-1 CrossRefPubMed

41.

Johansson E, Norén K, Sjövall J, Halldin MM (1989) Determination of Δ ¹-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 3:35–38. https://doi.org/10.1002/bmc.1130030109 CrossRefPubMed

Titel: Δ9-Tetrahydrocannabinol stimulation of estrogen receptor-positive MCF-7 breast cancer cell migration: Interfering interaction with the estrogenic milieu
verfasst von: Shuso Takeda
Masayo Hirao-Suzuki
Hironori Aramaki
Kazuhito Watanabe
Publikationsdatum: 30.12.2022
Verlag: Springer Nature Singapore
Erschienen in: Forensic Toxicology / Ausgabe 2/2023
Print ISSN: 1860-8965
Elektronische ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-022-00655-5

Neu im Fachgebiet Rechtsmedizin

30.10.2023 | Morphin | CME

Live-Webinar "Schulterschmerz in der Praxis gezielt managen"

Springer Medizin

Δ⁹-Tetrahydrocannabinol stimulation of estrogen receptor-positive MCF-7 breast cancer cell migration: Interfering interaction with the estrogenic milieu

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Rechtsmedizin

Nachweis eines Heroinkonsums

Knochentumoren des Kindes- und Jugendalters

Rezeptor-Tyrosinkinase-Fusionen in spindelzelligen Tumoren des Kindesalters

Periphere neuroblastische Tumoren im Kindesalter

Live-Webinar "Schulterschmerz in der Praxis gezielt managen"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Quantification of olanzapine and its three metabolites by liquid chromatography–tandem mass spectrometry in human body fluids obtained from four deceased, and confirmation of the reduction from olanzapine N-oxide to olanzapine in whole blood in vitro

Liquid chromatography with tandem mass spectrometric method for determination of 425 drugs and poisons in dried blood spots and application to forensic cases

Proteomic identification and quantification of Clostridium perfringens enterotoxin using a stable isotope-labelled peptide via liquid chromatography–tandem mass spectrometry

Analytical characterization and differentiation between threo- and erythro-4-fluoroethylphenidate

Detection of lisdexamfetamine and its metabolite d-amphetamine in urine and gastric contents collected from a cadaver at forensic autopsy

Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products

Neu im Fachgebiet Rechtsmedizin

Nachweis eines Heroinkonsums

Knochentumoren des Kindes- und Jugendalters

Rezeptor-Tyrosinkinase-Fusionen in spindelzelligen Tumoren des Kindesalters

Periphere neuroblastische Tumoren im Kindesalter